CELLIXIR
LIVE

Serial Number

79314660

Owner

CELLECTIS

Attorney

Mary Margaret L. O'Donnell

Filing Date

Mar 12, 2021

Add to watchlist:

No watchlists yet
View on USPTO

CELLIXIR Trademark

Serial Number: 79314660 • Registration: 7616514

CELLIXIR is a trademark filed by CELLECTIS on March 12, 2021. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals). The application is currently registered and active.

Owner Contact Info

CELLECTIS (10 trademarks)

102 avenue Gaston Roussel

Entity Type: 99

Trademark Details

Filing Date

March 12, 2021

Registration Date

December 24, 2024

Published for Opposition

November 5, 2024

Goods & Services

Pharmaceutical and veterinary preparations, namely, cells, tissues, and grafts engineering reagent for medical or veterinary purposes; diagnostic preparations for medical and veterinary use; living cells and cultures of microorganisms as well as protein arrays, synthetic peptides for the treatment of blood, genetic, and immune disorders and cancer and nucleic acid sequences and complexes of these molecules, namely, ribo-nucleo and desoxyribo-nucleo complexes, nucleo-proteo complexes for medical and veterinary use; living cells and cultures of microorganisms as well as proteins arrays, synthetic peptides and nucleic acids sequences and complexes of these molecules, namely, ribo-nucleo and desoxyribo-nucleo complexes, nucleo-proteo complexes for medical and clinical use for the treatment of genetic defects in gene therapy, viral and infectious diseases, cardiovascular diseases and cancer; diagnostic preparations for medical and veterinary use, in particular for the diagnosis and analysis of genetic defects, viral and infectious diseases, cardiovascular diseases and cancer; living cells, cultures of microorganisms, and proteins arrays, synthetic peptides and nucleic acids sequences and complexes of these molecules, namely, ribo-nucleo and desoxyribo-nucleo complexes, nucleo-proteo complexes for medical and veterinary use, in particular for medical and clinical use for the treatment of genetic defects in gene therapy, viral and infectious diseases, cardiovascular diseases and cancer

Chemicals and biochemical products for industrial and scientific use and not for medical or veterinary use, for transferring biological molecules into living cells and for integrating foreign nucleic acids into the genome of living cells; chemical and biochemical soluble substances and solutions for industrial use and not for medical or veterinary purposes, for the transfer of chemical or biological molecules into living cells and the integration of foreign nucleic acids into the genome of living cells; biological preparations for laboratory use, other than for medical and veterinary use; diagnostic preparations, other than for medical and veterinary use; peptide substrates, protein arrays and nucleic acids or complexes of these molecules, namely, ribo-nucleo and desoxyribo-nucleo complexes for clinical or medical laboratory use, for identifying genetic expression and protein location and integration of foreign nucleic acids into the genome of living cells; chemical and biochemical preparations for industrial and scientific use; chemical and biochemical soluble substances and solutions for industrial use and not for medical or veterinary purposes, for cellular and gene engineering and analysis in laboratories; Chemicals, namely, standard solutions and buffers used in analytical chemistry for transferring chemical and biological molecules into living cells, integration of foreign nucleic acids into the genome of living cells and transient production of proteins or nucleic acids; aqueous chemical and biochemical solutions containing nutrients for cultivating living cells for use in electroporation; biological cell and tissue cultures for laboratory use other than for medical and veterinary use; diagnostic reagents other than for medical and veterinary use; peptide substrates, protein array and nucleic acids or complexes of these molecules, namely, ribo-nucleo and desoxyribo-nucleo complexes, nucleo-proteo complexes for clinical or medical laboratory use, in particular for detecting and monitoring, and for integrating foreign nucleic acids into the genome of living cells and transient production of proteins; transfection reagents in the nature of chemical and biochemical reagents, used for transient production of proteins, other than for medical and veterinary use

Filing History

FINAL DECISION TRANSACTION PROCESSED BY IB
Jun 27, 2025 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Jun 10, 2025 FICS
FINAL DISPOSITION PROCESSED
Jun 9, 2025 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Mar 24, 2025 FICR
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Dec 24, 2024 NRCC
REGISTERED-PRINCIPAL REGISTER
Dec 24, 2024 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Nov 5, 2024 NPUB
PUBLISHED FOR OPPOSITION
Nov 5, 2024 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Oct 16, 2024 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Sep 30, 2024 CNSA
EXAMINER'S AMENDMENT ENTERED
Sep 30, 2024 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Sep 30, 2024 GNEN
EXAMINERS AMENDMENT E-MAILED
Sep 30, 2024 GNEA
EXAMINERS AMENDMENT -WRITTEN
Sep 30, 2024 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Sep 9, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Sep 9, 2024 CRFA
TEAS REQUEST FOR RECONSIDERATION RECEIVED
Sep 9, 2024 ERFR
NOTIFICATION OF FINAL REFUSAL EMAILED
Apr 4, 2024 GNFN
FINAL REFUSAL E-MAILED
Apr 4, 2024 GNFR
FINAL REFUSAL WRITTEN
Apr 4, 2024 CNFR
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Feb 14, 2024 RCCK
NEW REPRESENTATIVE AT IB RECEIVED
Nov 18, 2023 NREP
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Aug 10, 2023 RCSC
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Jan 26, 2023 RCSC
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Dec 27, 2022 OPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Dec 7, 2022 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Dec 7, 2022 OPNR
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Jun 12, 2022 GNS3
LETTER OF SUSPENSION E-MAILED
Jun 12, 2022 GNSL
SUSPENSION LETTER WRITTEN
Jun 12, 2022 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Apr 26, 2022 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Apr 25, 2022 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Apr 25, 2022 TROA
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Apr 25, 2022 CHAN
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Apr 25, 2022 TCCA
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Apr 25, 2022 ECDR
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Apr 25, 2022 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Apr 25, 2022 REAP
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Apr 25, 2022 COAR
REFUSAL PROCESSED BY IB
Nov 23, 2021 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Oct 29, 2021 RFCS
REFUSAL PROCESSED BY MPU
Oct 29, 2021 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Oct 28, 2021 RFCR
NON-FINAL ACTION WRITTEN
Oct 27, 2021 CNRT
ASSIGNED TO EXAMINER
Oct 12, 2021 DOCK
APPLICATION FILING RECEIPT MAILED
Jul 10, 2021 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jul 6, 2021 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Jul 1, 2021 REPR